Fresh analysis indicates that patients who stop using new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Published data in a prominent medical journal points out that while obese individuals can lose substantial amounts of their body weight while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals buying such treatments need to be informed of the potential of quick weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
That rate of regain suggests a reversion to starting mass within about 18 months.
Analyzing Therapies
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that people who shed pounds through lifestyle changes alone usually have a more gradual weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the way of the jabs explains the heightened weight return.
These medications imitate a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in appetite is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the treatment might need to be ongoing.
This opinion is supported by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension.
User Testimonies
People who have stopped the jabs describe a powerful resurgence of cravings.
"It felt as if something activating and I was suddenly ravenous," said a patient.
The struggle is worsened if users have not developed lasting lifestyle or habit changes during treatment.
Widespread Adoption
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is higher among women than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent fix and long-term success relies on combined lifestyle support.
